Among systemic treatments for plaque psoriasis, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were found to be associated with the highest Psoriasis Area and Severity Index (PASI) response rates.
Dermatological Disorders
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone. The 81-year-old man presented to the emergency department after a fall, which was eventually attributed to orthostatic hypotension. His medical history included atrial fibrillation and…
A review provides an update on current and emerging concepts of management for excessive hand sweating to help clinicians optimize therapeutic decision making.
Want to read more?
Please login or register first to view this content.